Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG:2252)
Hong Kong · Delayed Price · Currency is HKD 21.22
-0.76 (-3.46%)
Nov 21, 2025, 11:59 AM HKT
HKG:2252 Revenue
Shanghai MicroPort MedBot (Group) had revenue of 175.69M CNY in the half year ending June 30, 2025, with 269.07% growth. This brings the company's revenue in the last twelve months to 333.70M, up 113.60% year-over-year. In the year 2024, Shanghai MicroPort MedBot (Group) had annual revenue of 257.25M with 145.95% growth.
Revenue (ttm)
333.70M CNY
Revenue Growth
+113.60%
P/S Ratio
61.99
Revenue / Employee
753.28K CNY
Employees
443
Market Cap
22.67B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 257.25M | 152.66M | 145.95% |
| Dec 31, 2023 | 104.59M | 82.99M | 384.15% |
| Dec 31, 2022 | 21.60M | 19.45M | 904.79% |
| Dec 31, 2021 | 2.15M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.89B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |